Overview Avelumab Program Rollover Study Status: Active, not recruiting Trial end date: 2024-01-28 Target enrollment: Participant gender: Summary The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study. Phase: Phase 3 Details Lead Sponsor: EMD Serono Research & Development Institute, Inc.Collaborator: Merck KGaA, Darmstadt, GermanyTreatments: Antibodies, MonoclonalAvelumab